<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00908323</url>
  </required_header>
  <id_info>
    <org_study_id>HVTN 908</org_study_id>
    <secondary_id>10806</secondary_id>
    <nct_id>NCT00908323</nct_id>
  </id_info>
  <brief_title>Early Immune Responses to Vaccination - A Substudy to HVTN 205</brief_title>
  <official_title>Characterization of the Innate Immune Response to Candidate HIV Vaccines, an Ancillary Study to HVTN 205</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      HVTN 908 is a sub study of the HIV vaccine trial, HVTN 205. The purpose of this sub study is
      to better understand how a person's immune system responds to vaccines, particularly HIV
      vaccines. More specifically, researchers will determine whether early responses in the immune
      system help predict strong and long-lasting immunity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Some of the first HIV vaccines were designed to trigger neutralizing antibody responses as a
      way to prevent HIV infection. Unfortunately, the first versions of these vaccines were not
      able to achieve their desired response. An alternative strategy to the antibody approach is
      the stimulation of HIV-specific CD8 T-lymphocyte (CTL) responses. CTL responses were
      previously demonstrated to play an important role in the control of simian immunodeficiency
      virus (SIV), the HIV equivalent studied in rhesus macaque monkeys. Additionally, other
      studies suggest CTLs play an important role in viral control during chronic infection. Based
      on this information, several groups have shifted their focus to the development of CTL-based
      vaccines, some of which have entered advanced clinical trials.

      A DNA/rMVA vaccine strategy is structured to bring about both T cell and antibody responses.
      The primary vaccination is DNA based and will express only HIV proteins as a way to produce
      an HIV-focused immune response. A secondary, rMVA boost vaccination, which expresses both HIV
      and MVA proteins will ideally amplify the focused response of the initial vaccination. The
      DNA and rMVA are physically two different vaccinations given at separate times but together
      they make up one preventive regimen. Both vaccine components express non-infectious
      virus-like particles.

      The main study, HVTN 205 will evaluate the safety of and immune response to a two vaccine
      regimen in healthy, HIV-uninfected adults who never received an HIV preventive vaccine
      before. HVTN 205 will include two parts, Part A, in which the two vaccine regimen is compared
      to a placebo, and Part B, in which the two vaccine regimen will be compared to both a placebo
      and a single vaccine regimen with the rMVA vaccine.

      HVTN 908 is a sub study of HVTN 205, and will explore the innate immune response to candidate
      HIV vaccines. In particular, researchers will study whether early immune response following
      vaccination can predict strong and long-lasting immunity. They will also study whether
      varying types of vaccines promote different immune responses soon after vaccination.

      Only participants enrolled in HVTN 205 are eligible for HVTN 908. Approximately 50
      participants will be recruited for the duration of 12 months per participant. The study will
      last for a total of 2 years, including enrollment, follow-up, and analysis. Potential
      participants of the sub study will undergo a screening visit before eligibility can be
      determined. Screening may involve a physical exam, health history, and blood tests.

      There will be some additional visits for participants of HVTN 908 that are not included in
      the main study. Some main study visits may also take extra time for participants enrolled in
      the sub study. Blood samples will be taken at study visits. These samples are taken in
      addition to those for the main study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Blood concentrations of lymphocyte populations, dendritic cells, monocytes, and granulocytes</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentrations of cytokines and chemokines</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in PBMC gene expression relative to prevaccine levels of key genes expected to change, such as IP-10 and MCP-1</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">47</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <description>Participants receiving the JS7 DNA and MVA/HIV62 vaccinations in HVTN 205</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <description>Participants receiving the placebos of the JS7 DNA and MVA/HIV62 vaccines in HVTN 205</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>JS7 DNA vaccine</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA/HIV62 vaccine</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples 30 - 90 mL per visit
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants enrolled in HVTN 205
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled receipt of a vaccine or placebo in HVTN 205

          -  For participants in Part B of HVTN 205, enrollment in HVTN 908 and HVTN 205 at the
             same time

          -  HVTN 908 assessment of understanding: completion of a questionnaire prior to
             enrollment; demonstration of understanding for all questionnaire items answered
             incorrectly.

          -  Body weight of 50 kg (110 lbs) or more

          -  Hemoglobin of 12.0 g/dL or more for female volunteers, and 13.0 g/dL or more for male
             volunteers

          -  Negative HIV-1 and -2 blood test

        Exclusion Criteria:

          -  Clinically significant medical condition, physical examination finding, clinically
             significant abnormal laboratory results, or past medical history with clinically
             significant implications for current health. More information on this criterion can be
             found in the study protocol.

          -  Any medical, psychiatric, or occupational, or other condition that, in the judgment of
             the investigator, would interfere with, or serve as a contraindication to, protocol
             adherence, or a participant's ability to give informed consent

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erica Andersen-Nissen, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Vaccine CRS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bridge HIV CRS</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Vaccine and Prevention CRS</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Baker BM, Block BL, Rothchild AC, Walker BD. Elite control of HIV infection: implications for vaccine design. Expert Opin Biol Ther. 2009 Jan;9(1):55-69. doi: 10.1517/14712590802571928 . Review.</citation>
    <PMID>19063693</PMID>
  </reference>
  <reference>
    <citation>Browne EP, Littman DR. Myd88 is required for an antibody response to retroviral infection. PLoS Pathog. 2009 Feb;5(2):e1000298. doi: 10.1371/journal.ppat.1000298. Epub 2009 Feb 13.</citation>
    <PMID>19214214</PMID>
  </reference>
  <reference>
    <citation>Zwoli≈Ñska K. [Host genetic factors associated with susceptibility to HIV infection and progression of infection]. Postepy Hig Med Dosw (Online). 2009 Feb 24;63:73-91. Review. Polish.</citation>
    <PMID>19252466</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2009</study_first_submitted>
  <study_first_submitted_qc>May 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2009</study_first_posted>
  <last_update_submitted>March 25, 2015</last_update_submitted>
  <last_update_submitted_qc>March 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV Seronegativity</keyword>
  <keyword>HIV Preventive Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

